News
Agilent BioTek Cytation C10 Confocal Imaging Reader Enhanced with Innovative Water Immersion Technology
Agilent Technologies Inc. (NYSE: A) today announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. (OTC: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron
Chemed Corporation to Present at the BofA Securities 2023 Virtual Home Care Conference
Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2023 Virtual Home Care Conference on Monday, December 4, 2023, at 2:10 PM (ET).
The presentation will be
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
EQS-News: Formycon and Fresenius Kabi announce File Acceptance for FYB202, a biosimilar candidate to Stelara® (ustekinumab), by the U.S. Food and Drug Administration
Evolva convenes extraordinary general meeting (EGM) for 21 December 2023 to approve the sale of Evolva AG to Lallemand Inc.
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Owens & Minor Announces Upcoming Investor Day on December 6th
Owens & Minor, Inc. (NYSE: OMI) (the “Company”) today announced that it will host an Investor Day for investors and research analysts on Wednesday, December 6th at Convene in Boston, Massachusetts
EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
Charles River and Genetic Cures for Kids Announce Gene Therapy Manufacturing Collaboration
Charles River Laboratories International, Inc. (NYSE: CRL) and Genetic Cures for Kids Inc (GC4K), an Australian non-profit foundation focused on research programs and clinical trials to find cures
Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-term Growth Drivers and an Accelerated Path to Profitability
Novocure (NASDAQ: NVCR) today announced a series of actions to strengthen and optimize business operations to support near-term growth drivers and long-term value creation. The plan includes an
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Charles River Laboratories to Present at Evercore ISI Investor Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29th, at 9:10 a.m. ET
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals PLC
EQS-Adhoc: Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors
Edison issues update on ReNeuron Group (RENE): H124 results reaffirm focus on CustomEX™
EQS-News: Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea® (Aflibercept)